Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Therapy-Reference-Cited by-同舟云学术

Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Therapy

Published:2022-02-01 Issue:2 Volume:158 Page:189
ISSN:2168-6068
Container-title:JAMA Dermatology
language:en
Short-container-title:JAMA Dermatol

Author:

Tang Kimberly¹,Seo Jayhyun¹,Tiu Bruce C.¹²,Le Thomas K.³,Pahalyants Vartan¹²,Raval Neel S.¹²⁴,Ugwu-Dike Pearl O.¹,Zubiri Leyre⁵,Naranbhai Vivek⁵,Carrington Mary⁶⁷⁸,Gusev Alexander⁹,Reynolds Kerry L.⁵,LeBoeuf Nicole R.¹⁰,Asgari Maryam M.¹²¹¹,Kwatra Shawn G.³,Semenov Yevgeniy R.¹²

Affiliation:

1. Massachusetts General Hospital, Department of Dermatology, Boston

2. Harvard Medical School, Department of Dermatology, Boston, Massachusetts

3. Johns Hopkins University, Department of Dermatology, Baltimore, Maryland

4. Washington University School of Medicine, St Louis, Missouri

5. Massachusetts General Hospital, Department of Medicine, Division of Oncology, Boston

6. Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, Maryland

7. Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge

8. Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland

9. Dana Farber Cancer Institute, Department of Medicine, Boston, Massachusetts

10. Dana Farber Cancer Institute, Department of Dermatology, Boston, Massachusetts

11. Department of Population Medicine, Harvard Medical School, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

Dermatology

Link

https://jamanetwork.com/journals/jamadermatology/articlepdf/2787886/jamadermatology_tang_2022_br_210025_1643827859.16208.pdf

Reference9 articles.

1. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs.;Haslam;JAMA Netw Open,2019

2. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.;Puzanov;J Immunother Cancer,2017

3. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline.;Brahmer;J Clin Oncol,2018

4. Treatment outcomes of immune-related cutaneous adverse events.;Phillips;J Clin Oncol,2019

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis;Cancer Treatment Reviews;2024-09

2. Ophthalmic Immune-Related Adverse Events and Association with Survival: Results from a Real-World Database;American Journal of Ophthalmology;2024-09

3. Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study;The Lancet Oncology;2024-08

4. Construction of a nomogram with IrAE and clinic character to predict the survival of advanced G/GEJ adenocarcinoma patients undergoing anti-PD-1 treatment;Frontiers in Immunology;2024-07-24

5. Patient Out-of-Pocket Costs for Type 2 Diabetes Medications When Aging Into Medicare;JAMA Network Open;2024-07-09